616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)Jason M. Redman, James L. Gulley, Amy Hankin et al.|Annals of Oncology|2020Cited by 6
Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.Mohammad Atiq, Ravi A. Madan, Elias Bin Aris Chandran et al.|Journal of Clinical Oncology|2022Cited by 4
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.Mohammad Atiq, Ravi A. Madan, Elias Bin Aris Chandran et al.|Journal of Clinical Oncology|2022Cited by 3
1631P Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC)Jason M. Redman, James L. Gulley, Ravi A. Madan et al.|Annals of Oncology|2024Cited by 3